Fenoldopam Mesylate Versus Sodium Nitroprusside in the Acute Management of Severe Systemic Hypertension
- 1 June 1993
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 33 (6) , 549-553
- https://doi.org/10.1002/j.1552-4604.1993.tb04702.x
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertensionCritical Care Medicine, 1990
- Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension.Circulation, 1990
- Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension.Hypertension, 1990
- Comparative acute blood pressure reduction from intravenous fenoldopam mesylate versus sodium nitroprusside in severe systemic hypertensionThe American Journal of Cardiology, 1989
- Selective dopamine-1 agonist therapy in severe hypertension: Effects of intravenous fenoldopamJournal of the American College of Cardiology, 1988
- Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1‐receptor agonist, in hypertensive patients.British Journal of Clinical Pharmacology, 1988
- Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine1 agonist fenoldopam.Circulation, 1987
- The DA1 receptor agonist fenoldopam (SK & F 82526) is also an α2-adrenoceptor antagonistEuropean Journal of Pharmacology, 1985
- Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension.Circulation, 1984
- Sodium NitroprussideNew England Journal of Medicine, 1975